$AMGN

Amgen (AMGN) raised its fiscal 2026 revenue forecast to $38.8B, up 2.6% from prior guidance. Its stock has gained 15.2% since the announcement, outperforming the S&P 500. The company's six key growth drugs grew 26% YoY, offsetting declines in older drugs. Amgen's share price is up 18.9% from its 200-day average, indicating an intact uptrend. The stock trades at 26.8x earnings, higher than the S&P 500's 22.7x.

A congressional analysis estimates President Trump increased his pharmaceutical stock holdings from $1.7M in 2024 to $56.2M in 2025, benefiting from policies that raised drug prices. Merck, Johnson & Johnson, AbbVie, Pfizer, and Amgen were among the companies that gained. Merck reported $22.5B in profits in 2025, a 16% increase.

The weight-loss drug market is growing rapidly, with analysts projecting $100B in annual sales by 2030. Novo Nordisk and Eli Lilly lead, but competitors like Pfizer, Roche, Amgen, and others are developing new treatments. Key drugs include Novo's amycretin and CagriSema, Lilly's EloraTZP, and Pfizer's PF-3944, with varying efficacy in trials.

SPDR Dow Jones Industrial Average ETF (DIA) sold $309.2M in stocks on Oct. 14, reducing all 30 holdings. Largest sales were GS ($31.3M), CAT ($26.7M), and MSFT ($19.0M). DIA manages $44.93B with a 0.16% expense ratio and a 9.64% YTD return. No new positions were opened.

AI stocks faced volatility, prompting capital rotation into pharmaceuticals. Eli Lilly (LLY) and AbbVie (ABBV) neared record highs, with LLY at $1,251.61 and ABBV at $283.40. Healthcare ETF XLV hit $177.19. LLY's gains were driven by its GLP-1 dominance and M&A activity, while ABBV's rally followed positive Skyrizi data. Other large-cap pharma stocks also rose, but biotech ETF XBI declined 2.8% over a month.

Amgen (AMGN) faces scrutiny over its 2027 bull case, which assumes FDA's CNPV program and obesity market growth will boost its valuation. Critics argue Amgen lacks supply chain infrastructure, CNPV's future is uncertain, competitors like Novo Nordisk have a head start, and legacy drugs are declining rapidly. The company's stock may be overvalued.

Amgen (AMGN) ranks second in sales growth and operating margin among peers. Despite outperforming Johnson & Johnson (JNJ) in growth and margins, Amgen trades at a lower P/E. Amgen's Q2 2026 report showed growth in key drugs like Repatha, but declines in Prolia and XGEVA due to biosimilar competition. The company raised its 2026 revenue guidance to $38.2B-$39.4B, with a midpoint of $38.8B, up from $37.8B. Operating expenses are expected to rise in Q3, potentially impacting margins.

Eli Lilly (LLY) has seen significant growth due to its GLP-1 weight-loss drugs, Mounjaro and Zepbound, with a market cap of $1.1 trillion. Competition is intensifying, with companies like Novo Nordisk (NVO), Viking Therapeutics (VKTX), Amgen (AMGN), and Regeneron (REGN) developing new treatments. GLP-1 drugs are also impacting consumer spending, affecting companies like General Mills (GIS). Absci (ABSI) and Telescope Innovations (TELIF) are leveraging AI to aid drug development.

Amgen (AMGN) launched a Phase 1 study to compare the bioavailability of its bone drug Evenity (romosozumab) when given as one 210 mg injection or two smaller injections. The study aims to find the most efficient delivery method, which could support long-term use and franchise value. The trial is ongoing, with the latest update filed on 12 October 2026. Investors view this as a positive sign of continued investment in the Evenity platform.

Guggenheim maintained a Neutral rating on Amgen (AMGN) but lowered its price target from $388 to $378. Amgen's stock is currently trading at $417.57, which is 13.4% above its GF Value™ of $368.11, indicating overvaluation. The company has a GF Score™ of 85/100, showing strong financial health and profitability. Insider activity shows significant selling in the last three months.